tbuckley/cabot-search huggingface dataset:
Self Unanimity
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Dog's Medical Dictionary: An Encyclopaedia of the Diseases, Their Diagnosis and Treatment, Poisons and Their Antidotes, and the Physical Development of the Dog
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Albumin Testing.
Authors: C. D. Nelson
Journal: JAMA (1896)

Greeley, Colo., July 22, 1896. <h3>To the Editor:</h3> —In ourJournalof April 11, 1896, p. 732, Dr. J. W. O'Neill describes a new apparatus for the cold nitric acid test for albumin. A more available way, giving a large surface of contact for the urine and acid, with very little mixing of the fluids, is to put the urine to the depth of about half an inch into a beaker of suitable size,<i>e</i>.<i>g</i>., two inches in diameter. Take up about m xlv of the acid with a pipette. Put the point of the pipette down through the urine to the bottom of the beaker and let the acid escape slowly, especially at first. One way to be sure that the acid escapes slowly is to watch the top of the column of acid in the pipette. If this goes down slowly one may be pretty sure that
Supplementation with branched-chain amino acids improves muscle mass of cirrhotic patients with sarcopenia
Authors: Marta Hernández Conde, Elba Llop, Beatriz Tormo, Christie Perelló, Marta López-Gómez, Javier Abad Guerra, Luis Rodríguez, José Luis Martínez Porras, Natalia Fernández Puga, Carlos Ferre, Maria Trapero, Enrique Fraga, José Luis Calleja Panero
Journal: Journal of Hepatology (2020)
Fight against tobacco addiction moving into international arena
Authors: M. F. Goldsmith
Journal: JAMA (1990)

THE TOBACCO LEAF carved into the speaker's rostrum of the US House of Representatives the cash crop that financed the American Revolution—symbolizes a product to which the federal government has paid homage for more than 200 years, says Rep Chester G. Atkins (D, Mass). At the recent World Conference on Lung Health, Atkins and a host of other speakers called for an end to such adulation. "Tobacco money explains the reluctance of Congress to tolerate any regulation of tobacco," adds C. Everett Koop, MD, former surgeon general of the US Public Health Service. It also accounts, says Atkins, for the moral climate that recently allowed the US international trade representative, Carla Hills, to decide "for the fourth time in four years... that cigarettes are a harmless commodity." However, this is an attitude that must be abandoned in view of the health threat posed by the golden leaf, Atkins says, insisting:
SPAIN
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Premature Mortality in New Hampshire
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE HOUSE OF BARTHOLINUS
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Casopis Lekaru Ceskych, Praha
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
index to advertisers
Journal: JAMA (1975)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Proportionate mortality trends: 1950 through 1986
Authors: J. E. Sutherland
Journal: JAMA (1990)

Mortality trends in the United States from 1950 through 1986 were analyzed for the conditions that are or have recently been among the six leading causes of death. The age-adjusted mortality rate for all causes has decreased from 841.5 to 541.7 per 100 000 population. Cause-specific, age-adjusted mortality rates have declined from 1950 through 1986 for cerebrovascular disease, injuries, perinatal conditions, heart disease, and influenza and pneumonia. Time trends in the proportion of persons dying of each of these diseases, however, have varied; the proportion dying of cerebrovascular disease, injuries, and perinatal conditions has decreased, and the proportion of persons dying of heart disease and influenza and pneumonia has remained fairly stable from 1950 through 1986. During this same time, age-adjusted death rates have increased for chronic obstructive pulmonary disease and have remained fairly stable for malignant neoplasms, while the proportions of persons dying of chronic obstructive pulmonary disease and malignant neoplasms have increased dramatically. For people aged 35 to 64 years, malignant neoplasms have now overtaken heart disease as the leading cause of death. For those aged 65 years and older, heart disease remains the leading cause of death, accounting for almost 50% of all deaths in persons 85 years and older. (<i>JAMA</i>. 1990;264:3178-3184)
SI-SA
Authors: Richard Donze
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 10902: Association Between Funding Sources and the Scope and Outcomes of Cardiovascular Clinical Trials: A Systematic Review
Authors: Muthiah Vaduganathan, Ayman Samman-Tahhan, Lampros Papadimitriou, Vasiliki V Georgiopoulou, Stephen J Greene, Andreas P Kalogeropoulos, Eric Peterson, Gregg C Fonarow, Mihai Gheorghiade, Javed Butler
Journal: Circulation (2015)

Introduction: Limited data are available exploring trends and influence of funding sources on cardiovascular clinical trials scope and outcomes. Methods: We abstracted data from all phase II to IV cardiovascular clinical trials from 2001 to 2012 published in the 8 highest Web of Science impact factor journals using both a PubMed database and manual journal search. Results: Of the 1,224 trials evaluated, 581 (47.5%) were funded by industry, 273 (22.3%) by universities or other non-profit organizations, 159 (13%) by governments, 127 (10.4%) were jointly funded, and 84 (6.9%) did not report funding source. Proportion of industry and government funded trials trended down, while the proportion of non-profit and jointly-funded trials increased over time (P&lt;0.001; Figure ). Non-profit trials had the highest enrollment rates (P&lt;0.001), while industry trials (44.1%) more commonly evaluated new therapies vs. placebo compared with other funding sources (P&lt;0.001; Table ). Positive outcomes were more likely to be reported by industry (65.6%) and non-profit (66.3%) trials compared to government (50.3%) or jointly-funded (45.7%) trials (P&lt;0.001). After accounting for major trial characteristics, industry-funded (OR 2.37; 95% CI 1.61-3.49) and non-profit (OR 1.91; 95% CI 1.24-2.94) studies were more likely to report favorable outcomes compared with government-sponsored trials. Conclusions: Funding sources of cardiovascular clinical trials are associated with various aspects of trial conduct and outcomes. Further research is required to explore the systematic influence of funding mechanisms on contemporary cardiovascular clinical trials.
INTRODUCTORY ADDRESS.
Authors: GEORGE M. STERNBERG
Journal: JAMA (1895)

<h3>Ladies and Gentlemen:</h3> —The Faculty of the Medical Department of Georgetown University has decided upon a new departure in medical teaching in the District of Columbia, and by their invitation I am here to deliver an address upon an occasion which they very properly consider to be one of unusual interest to the medical profession and to the citizens generally in this great and rapidly growing capital city. Heretofore the courses of instruction have been so arranged that students who are occupied, during the official hours, in the various government offices located in this city could take advantage of them. This has no doubt made it possible for many industrious and deserving men to obtain the degree of Doctor of Medicine who would otherwise have been unable to do so. And I presume that a fair proportion of those who have pursued their medical studies under these circumstances have become
Nicotine Addiction
Authors: Neal L. Benowitz
Journal: New England Journal of Medicine (2010)

Cigarette smoking remains a leading cause of preventable disease and premature death in the United States and other countries.On average, 435,000 people in the United States die prematurely from smoking-related diseases each year; overall, smoking causes 1 in 5 deaths.The chance that a lifelong smoker will die prematurely from a complication of smoking is approximately 50%. 1 Tobacco use is a major cause of death from cancer, cardiovascular disease, and pulmonary disease.Cigarette smoking is also a risk factor for respiratory tract and other infections, osteoporosis, reproductive disorders, adverse postoperative events and delayed wound healing, duodenal and gastric ulcers, and diabetes.In addition, smoking has a strong association with fire-related and trauma-related injuries.Smoking-caused disease is a consequence of exposure to toxins in tobacco smoke.Although nicotine plays a minor role, if any, in causing smoking-induced diseases, addiction to nicotine is the proximate cause of these diseases.Currently, about 45 million Americans smoke tobacco.Seventy percent of smokers say they would like to quit, and every year, 40% do quit for at least 1 day. 2 Some highly addicted smokers make serious attempts to quit but are able to stop only for a few hours. 3Moreover, the 80% who attempt to quit on their own return to smoking within a month, and each year, only 3% of smokers quit successfully.Unfortunately, the rate at which persons -primarily children and adolescents -become daily smokers nearly matches the quit rate, so the prevalence of cigarette smoking has declined only very slowly in recent years. 2 This article focuses on nicotine as a determinant of addiction to tobacco and the pharmacologic effects of nicotine that sustain cigarette smoking.Tobacco addiction (like all drug addictions) involves the interplay of pharmacology, learned or conditioned factors, genetics, and social and environmental factors (including tobacco product design and marketing) 4 (Fig. 1).The pharmacologic reasons for nicotine use are enhancement of mood, either directly or through relief of withdrawal symptoms, and augmentation of mental or physical functions. BRAIN MECHANISMS NICOTINIC ACETYLCHOLINE RECEPTORSInhalation of smoke from a cigarette distills nicotine from the tobacco in the cigarette.Smoke particles carry the nicotine into the lungs, where it is rapidly absorbed into the pulmonary venous circulation.The nicotine then enters the arterial circulation and moves
DISPOSABLE SYRINGES AND NEEDLES
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
session 6 – extranodal lymphoma
Authors: U Novak, A Rinaldi, I Kwee, V Murty, S Nandula, P Rancoita, M Cerri, D Rossi, G Gaidano, E Zucca, M Compagno, L Pasqualucci, R Dalla Favera, G Bhagat, F Bertoni, J Goda, M Gospodarowicz, M Pintilie, W Wells, D Hodgson, A Sun, B Patterson, N Laperriere, M Crump, R Tsang
Journal: Annals of Oncology (2008)
Mutant (MT) <i>KRAS</i> codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab).
Authors: Marc Peeters, Jean-Yves Douillard, Eric Van Cutsem, Salvatore Siena, Kathy Zhang, Richard Thomas Williams, Jeffrey S. Wiezorek
Journal: Journal of Clinical Oncology (2012)

383 Background: Pmab is a fully human monoclonal antibody against the epidermal growth factor receptor (EGFR). Significant improvement in progression-free survival (PFS) was demonstrated in pts with wild-type (WT) KRAS mCRC treated with pmab+FOLFOX4 (1 st -line; study 20050203), pmab+FOLFIRI (2 nd -line; study 20050181), and pmab monotherapy (study 20020408). In mCRC, mutations in KRAS codons 12 and 13 are established biomarkers for lack of clinical benefit to anti-EGFR therapies. We retrospectively examined individual MT KRAS codon 12 and 13 alleles as prognostic and predictive biomarkers of response in three phase 3 studies. Methods: Pts were randomized to receive FOLFOX4, FOLFIRI, or best supportive care +/- pmab 6.0 mg/kg Q2W in studies 20050203, 20050181, and 20020408, respectively. The MT KRAS codon 12 and 13 alleles (G12A, G12C, G12D, G12R, G12S, G12V, G13D) were detected using the Therascreen K-RAS Mutation Kit (Qiagen). Results: MT KRAS codon 12 and 13 alleles were detected in 40% (440/1096), 45% (486/1083), and 43% (184/427) of pts in studies 20050203, 20050181, and 20020408, respectively. MT KRAS allele distribution was conserved across studies and balanced between treatment arms. Baseline demographic and clinical features were comparable between all MT KRAS allele subgroups. Across all studies, no single MT KRAS allele was consistently prognostic for PFS or overall survival (OS) in the control arm-treated pts. Similarly, no single MT KRAS allele was a consistent positive or negative predictive factor for PFS or OS in pmab-treated pts. Only in the pmab+FOLFOX4 arm of study 20050203 were G13D (unfavorably) and G12V (favorably) significantly associated with OS. Response rates were similar between MT KRAS allele groups in the 1 st - and 2 nd -line mCRC treatment setting. Finally, in analyses of pts pooled from all 3 trials, only the G12A KRAS allele emerged as a significant negative predictive factor for OS. Conclusions: The lack of consistent results across three lines of therapy indicates pts with MT KRAS codon 12 or 13 alleles are unlikely to respond to pmab therapy. Currently, only pts with WT KRAS mCRC should be treated with pmab.